Crenolanib inhibits retinal fibrosis associated with resistance to anti-VEGF in neovascular age-related macular degeneration in retinal Müller cells

Author:

Joo Jin-Ho1,Chung Junkyu2,Seo Jung-Woo3,Moon Sang Woong3

Affiliation:

1. The Catholic University of Korea

2. Gyeong-in Regional Military Manpower Administration

3. Kyung Hee University Hospital at Gangdong

Abstract

Abstract Backgorund Anti-vascular endothelial growth factor (VEGF) treatment for neovascular age-related macular degeneration (NVAMD) may cause fibrosis in primary cultured mouse retinal Müller cells (PMCs), resulting in resistance to treatment. This study aimed to confirm the decrease in the expression of fibrosis-related proteins after treatment with platelet-derived growth factor receptor (PDGFR) inhibitor. Methods PMCs were treated with anti-VEGF, bevacizumab, and PDGF, for 24 and 72 h, and the expression of fibrosis-related proteins, inflammatory cytokines, and PDGFR was confirmed. After 72 h of co-treatment of PMCs with bevacizumab and crenolanib, a PDGFR inhibitor, fibrosis-related protein expression was confirmed. Results When PMCs were treated with 1 mg/mL bevacizumab for 72 h, the expression of VEGF and inflammatory cytokines decreased, and the expression of fibrosis-related proteins and PDGFR-β increased. When PMCs were treated with 100 ng/mL PDGF-B for 72 h, the expression of VEGF and inflammatory cytokines increased, and the expression of fibrosis-related proteins and PDGFR-β decreased. When PMCs were treated with 1 mg/mL bevacizumab and 5 nM crenolanib, the expression of fibrosis-related proteins decreased. Conclusion If PMCs are treated with anti-VEGF agents for a long time, fibrosis may occur that may lead to resistance to NVAMD treatment. When PMCs are treated with anti-VEGF and crenolanib, a PDGFR inhibitor, the expression of fibrosis-related proteins is reduced.

Publisher

Research Square Platform LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3